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ABSTRACT 
During the last century, transfusion of blood components has become a prerequisite for 
treatment in many clinical settings. The availability of plastic bags and methods for 
centrifugation and separation of blood cells, has enabled processing of whole blood into 
blood cell components, and made it possible to optimize transfusion therapy, as well as 
storage conditions. Automation of the processes has been introduced, which increases 
reproducibility and standardization of the prepared components. 
Recommendations of leukocyte reduction to minimize side-effects caused by 
concomitant leukocytes have resulted in development in different types of filters. 
Today, universal leukocyte reduction is practice in many countries and in Sweden, a 
majority of the blood components are leukocyte reduced.  
For the immunosuppressed patients, who are at risk of developing transfusion 
associated graft-versus host disease attributed to passenger T-lymphocytes, there is 
need for further treatment of the blood components to restrain the proliferation of T-
lymphocytes, and hence prevent TA-GVHD. The prevalent method has been gamma 
irradiation, and in recent years X-ray irradiation has been available as another 
alternative to gamma irradiation from radioactive sources.  
The studies included in the present thesis focus on 1) preparation techniques for 
leukocyte reduction of whole blood which saves platelet, and results in preparation of 
erythrocytes, plasma and platelets, 2) automated preparation of leukocyte reduced 
platelets from pooled buffy coats and standardization of platelet content by selection of 
buffy coats, 3) evaluation of platelet additive solutions with different composition, with 
the aim to optimize storage conditions and 4) effects of gamma- and X-ray irradiation 
on platelets during storage. 
The results indicate that leukocyte reduction of whole blood with a filter that saves 
platelets results in blood components with sufficiently low leukocytes, satisfactory 
recovery of erythrocytes and platelets, and high quality as measured by in vitro 
parameters, which were maintained during storage. 
Automated preparation with OrbiSac of leukocyte reduced platelets from pooled buffy 
coats and standardization of platelet content by selection of buffy coats was introduced. 
Prepared platelets displayed in vitro characteristics equivalent to the previous manual 
method, during storage for 7 days. Moreover, the platelet count variation was  
reduced. 
Evaluation of different platelet additive solutions concluded that addition of phosphate 
is beneficial for storage of platelets. This finding has had an impact on development of 
the next generations of platelet additive solutions.  
Effects of different irradiation equipments were studied. No major deleterious effects of 
gamma irradiation on platelets during storage were identified. For X-ray irradiation 
previous data are scarce, especially for platelets, and our results imply that X-ray 
irradiation does not compromise the quality of platelets during storage for 7 days. 
 
The studies all represent new options for blood component preparation, which has 
enhanced efficacy and safety. 
  
  
 LIST OF PUBLICATIONS 
 
I Larsson S, Gulliksson H, Paunovic D. Evaluation of a whole-blood WBC-
reduction filter that saves platelets: in vitro studies. 
Transfusion 2001;41:534-539. 
 
II Larsson S, Sandgren P, Sjödin A, Vesterinen M, Gulliksson H. Automated 
preparation of platelet concentrates from pooled buffy coats: in vitro studies 
and experiences with the OrbiSac system. 
Transfusion 2005;45:743-751. 
 
III Gulliksson H, Larsson S, Kumlien G, Shanwell A. Storage of Platelets in 
Additive Solutions: Effects of Phosphate. 
Vox Sang 2000;78:176-184. 
 
IV Larsson S, Sandgren P, Källman A-S, Lundahl J, Gulliksson H. Irradiation of 
platelets for transfusion with two different techniques: Irradiation with cesium 
and X-rays.  
Submitted (Transfusion). 
 
 
  
CONTENTS 
1  INTRODUCTION ........................................................................................ 1 
1.1  Platelet preparation-short historical background ............................... 1 
1.2  Platelet biology and function .............................................................. 1 
1.3  Preparation of platelets ....................................................................... 3 
1.3.1  Preparation of platelets from whole blood ............................ 3 
1.3.2  Platelet prepared by apheresis ................................................ 5 
1.4  Storage of platelets ............................................................................. 5 
1.5  Platelet Additive Solution ................................................................... 7 
1.6  Leukocyte reduction of platelets ...................................................... 10 
1.7  Transfusion associated Graft versus Host Disease .......................... 11 
1.8  Irradiation of platelets ....................................................................... 13 
1.9  Quality assessment of platelets ........................................................ 14 
1.10  Platelets for transfusion .................................................................. 16 
2  AIMS .......................................................................................................... 19 
3  MATERIAL AND METHODS ................................................................. 20 
3.1  Preparation and storage of platelets ................................................. 20 
3.2  Bacterial screening of platelets ......................................................... 23 
3.3  Irradiation of platelets ....................................................................... 23 
3.4  In vitro analysis ................................................................................. 23 
3.4.1  Cellular and metabolic parameters ...................................... 23 
3.4.2  Functional parameters .......................................................... 24 
3.5  Statistical analysis ............................................................................. 24 
4  RESULTS AND DISCUSSION ................................................................ 25 
4.1  Paper I ............................................................................................... 25 
4.2  Paper II .............................................................................................. 26 
4.3  Paper III ............................................................................................. 27 
4.4  Paper IV ............................................................................................ 28 
5  CONCLUDING REMARKS ..................................................................... 30 
6  FUTURE PLANS ....................................................................................... 31 
6.1  Patient study ...................................................................................... 31 
6.2  Pneumatic tube transport .................................................................. 31 
6.3  Washing of platelets ......................................................................... 31 
7  SVENSK SAMMANFATTNING ............................................................. 32 
8  ACKNOWLEDGMENTS ......................................................................... 34 
9  References ................................................................................................... 35 
 
  
LIST OF ABBREVIATIONS 
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SAGMAN Saline-adenine-glucose-mannitol 
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TNF-α Tumor necrosis factor-alpha 
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1 INTRODUCTION 
1.1 PLATELET PREPARATION-SHORT HISTORICAL BACKGROUND 
Blood component preparation and component therapy was a new concept made 
possible by development of the plastic blood container in the 1950s, as well as 
techniques and devices which allowed centrifugation and separation. Until then, 
transfusion of whole blood was the prevailing method (1). Duke reported already 1910 
the importance of platelets to stop bleeding, although at that time fresh whole blood 
was transfused (2). 
Platelet rich plasma prepared by centrifugation of whole blood was the first available 
platelet concentrate (PC). Four to six units transfused were considered as an adequate 
platelet dose to an adult patient. During the decades to come, increasing knowledge 
about platelet metabolism, development of gas permeable platelet storage containers 
and additive solutions, has resulted in platelets with maintained quality during 5-7 days 
of storage as shown by several in vitro and in vivo studies. The application of methods 
to reduce leukocytes and inactivate lymphocytes and pathogens without compromising 
the quality of platelets, have increased the safety for transfusion recipients. 
 
1.2 PLATELET BIOLOGY AND FUNCTION 
Platelet are small anucleate cell fragments, with a diameter of approx. 2µm, with a 
medium volume of 7-9 fL in the resting state, formed as a small disc. Due to light 
refraction by their discoid form, the “swirling” phenomenon is seen, which is often 
used as a gross measure of platelet viability (3). The number of circulating platelets in 
healthy individuals shows a great variation, with a concentration of 150-400 x 109/L, 
and a life span of 7-10 days. Platelets originate from megakaryocytes, formed in the 
bone marrow, derived from hematopoietic stem cells further developed in response to 
different growth factors and cytokines. Thrombopoeitin, produced primarily in the 
liver, is the principal regulator of megakaryocyte development and platelet production. 
ABO-, HLA class I and human platelet antigens (HPA) are expressed on the surface, 
and may all be the target of alloantibodies, resulting in refractoriness to transfusion.  
 
Intracellularly, the platelets have two network of internal membranes, the open 
canicular system and the dense tubular system. The platelet also contain different types 
of granula: α-granules, dense bodies and lysosomes, where the α- granules contain 
adhesive proteins, e.g. fibrinogen, fibronectin, thrombospondin and von Willebrand 
Factor, vWF, and the dense bodies is a source of different activating substances, as 
adenosine diphosphate (ADP), serotonin and calcium.  
Upon activation, the granulae form a continuum with the open canicular system and 
releases its content of adhesive and procoagulant substances, exposing new antigenic 
determinants on the surface, which initiates and augments the hemostatic process. 
Also present in the cytoplasm, are the mitochondria, which have importance for the 
energy production. Figures 1-4 shows the ultrastructure and different shapes of 
platelets. 
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Figure 2.Transmission electron 
microscopy (TEM) image from a platelet 
at day 7 showing lucent granules and 
very few glycogen particles in the 
cytoplasm. (Per Sandgren, Kjell 
Hultenby) 
Figure 1.Transmission electron 
microscopy (TEM) image showing 
normal ultrastructure including 
mitochondria, α-granules, dense 
granules and glycogen in clusters 
from a fresh platelet at day 1. (Per 
Sandgren, Kjell Hultenby) 
Figure 3.Scanning electron microscopy (SEM) picture of 
discoid platelets in a BC platelet concentrate, stored for 1 
day in PAS-II. (Per Sandgren, Kjell Hultenby) 
Figure 4. Scanning electron microscopy (SEM) picture of 
spherocytical platelets in a BC platelet concentrate, stored 
for 14 days in PAS-II. (Per Sandgren, Kjell Hultenby) 
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The platelets play a crucial role in primary hemostasis, i.e. the initial formation of a 
hemostatic plug, at the site of a damaged endothelium, but also for initiating and 
augmenting the coagulation process. 
The triggering event is a vascular injury, which exposes subendothelial collagen and 
vWF, to which platelets adhere by binding of the GpIba, which by intracellular 
signaling leads to degranulation of substances that mediates further adhesion and 
aggregation of platelets, and subsequent stabilization of the hemostatic plug by fibrin 
polymerization. 
 
In addition, platelets has been found to exert many other important functions, as in 
tissue regeneration (4-9), due to the secretion of growth factors, which is applied in 
various clinical settings, and as part of the immune system (10-12). 
 
 
1.3 PREPARATION OF PLATELETS 
Preparation of platelets is done either with whole blood as source or by apheresis 
technique. The platelets can be suspended in concomitant plasma from the donors, or in 
a combination of plasma and platelet additive solution, and thereby will be influenced 
by the anticoagulant used. For whole blood donations, CPD is used, whereas ACD is 
commonly used in apheresis, which will be discussed in later sections. 
 
1.3.1 Preparation of platelets from whole blood 
1.3.1.1 Separation of blood cells by centrifugation  
Separation of blood cells by centrifugation is based on their sedimentation rate, 
according to their size and density, see Table 1. If anticoagulated blood is left in a 
blood bag, the cells will sediment due to gravity. To make this process faster, 
centrifugation is applied, the process being accelerated by higher g-force. The 
erythrocytes will sediment to the bottom of the bag, whereas leukocytes and platelets 
will settle on the top of the erythrocytes.  
During centrifugation, erythrocytes and leukocytes sediment faster, due to their higher 
density, whereas platelets sediment slowly. If the centrifugation is stopped at a point 
where erythrocytes and leukocytes have sedimented, but the platelets are still present in 
the plasma, platelet-rich plasma can be recovered. On the other hand, if centrifugation 
is continued long enough for the platelets to sediment, the platelets are instead 
recovered within the buffy coat. Both g-force and time of centrifugation will determine 
the separation of cells.  
 
Table1. Density of blood cells and plasma Ref: Guide to the preparation, use and quality assurance of 
blood components, 16th ed., Council of Europe 2010 
 Mean Density (g/mL) Mean Volume (10-15L; fL) 
Plasma 1,026  
Platelets 1,058 9 
Monocytes 1,062 470 
Lymphocytes 1,070 230 
Neutrophils 1,082 450 
Red cells 1,100 87 
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1.3.1.2 Preparation of platelets from platelet-rich plasma 
For platelets (PLTs) recovered from whole blood donation, the platelet rich plasma 
(PRP) method was the first to be practiced: the whole blood, kept at 20-24°C, for a 
maximum of 24 hours before preparation, is subjected to a relatively short, low g-force 
centrifugation (“soft spin”, up to 1000 g) leading to sedimentation of the erythrocytes 
and leukocytes, whereas the platelets are captured within the plasma fraction. In a 
second centrifugation step of the PRP, with a greater g-force (“hard spin”, approx. 
3000  g), the platelets are pelleted to the bottom of the bag and the major part of the cell 
free supernatant plasma is extracted. Subsequently, the platelets are resuspended in the 
retained volume of plasma (40-70 ml). The platelet content is variable, due to variations 
in donor platelet concentration, and in preparation. Platelet content shall meet the 
quality criteria according to European regulations, i. e. 200 x109PLTs/ unit, which 
usually corresponds to 4-6 pooled units, or a minimum of 60 x 109 PLTs/single 
unit (13). Regulation in USA requires a minimum of 5,5 x 109 PLTs/unit (14). 
Preparation of PRP is the main method to produce PC from whole blood in USA. 
 
1.3.1.3 Preparation from buffy coats 
A principally new method was introduced in the 1980s (15), where the whole blood 
was subjected to an initial centrifugation with high g-force (“hard spin”, approx 
3000 g), which forces all cells, i. e. erythrocytes, leukocytes and platelets to sediment 
according to their relative density, resulting in a thin layer of leukocytes and platelets 
on top of the erythrocytes. The thin layer of leukocytes and platelets, barely visible for 
the eye, called the “buffy coat” (BC) layer, consists of approx. 70-90% of leukocytes 
and up to 70-80% of the platelets from the original whole blood donation (16-18). The 
BC is separated into a bag in a following preparation step, by automated separation 
technique or by manual press, together with an amount of plasma intended for 
suspension of the platelets. The platelets are extracted from the buffy coat bag by an 
additional centrifugation (“soft spin”) resulting in sedimentation of the leukocytes, and 
a platelet-rich plasma supernatant which is transferred to a platelet storage container. 
Initially, single units of buffy coat platelets were prepared (15), followed later by a 
method with pooling of BC, usually 4-6 BCs (16), to increase the yield and the 
centrifugation conditions. This results in a platelet unit with an adequate dose for an 
adult patient (>200x 109 PLTs/unit)(13). 
Preparation of BC-PC is practiced in many European countries. In Sweden it accounts 
for approx. 70 % of the annual production (19), and at our clinic the proportion is 
approx. 85%. 
During the last decade, different equipment for automation in preparation of platelets 
from buffy coats has been developed, i.e. the OrbiSac Buffy-coat system (Terumo 
BCT, former Caridian BCT), and the TACSI system (Terumo BCT). 
The OrbiSac Buffy-coat system, which is evaluated in this thesis (Paper II), and by 
other authors (20-25), will be addressed in later sections. The Terumo Automated 
Centrifuge and Separation Integration (TACSI) system that was introduced in 2007, 
which produces six platelet units per process, has also been validated (26, 27). 
 
Devices to automate almost all processing steps for blood component preparation from 
whole blood have been developed, the Atreus system (Terumo BCT, former Caridian 
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BCT) being the first example. The Atreus system can be configured into different 
protocols, among which BC can be obtained (protocol 2C+)(28-30). The most recent 
configuration (protocol 3C) produces one unit of red blood cells (RBC), one unit of 
plasma and one unit of platelets per process, which results in platelets unit that may be 
transfused as single, or pools of 4-6 units. 
 
1.3.2 Platelet prepared by apheresis 
Platelets prepared by apheresis technique was introduced in the 1960s (31), and the 
development has led to apheresis equipments with continuous flow-devices with plastic 
disposable sets, using single-needle access and in-process systems for leukocyte 
reduction (32). With apheresis technique, whole blood is drawn and mixed with 
anticoagulant, and separated into cell fractions due to their relative density by 
centrifugation, the platelet-rich plasma fraction is collected into a platelet storage bag, 
and the remaining cells and most of the plasma is returned to the donor. In this way, it 
is possible to obtain a larger number of platelets from a single donor, sufficient for up 
to 4 transfusion doses, which is a advantages when platelets of a certain type is 
required, e.g. HLA-matched or HPA1a-negative. Also, the patient is exposed to fewer 
donors, with less risk of viral transmission. 
 
 
1.4 STORAGE OF PLATELETS 
The demand for platelets for transfusion are steadily increasing over the years, and 
readily accessible platelets are needed in many clinical situations, such as massive 
bleeding in conjunction with trauma, transplantation etc. 
 
Over the years, increasing knowledge about platelet metabolism, effects on storage at 
different temperatures and the development of new plastic materials and storage 
solutions has made it possible to prolong the shelf life of stored platelets, with 
preservation of haemostatic effect. 
 
As for whole blood, storage in the refrigerated state was initially practiced also for 
storage of platelets, but was found to lead to rapid clearance after transfusion. Platelets 
refrigerated for more than 12 to 24 hours do not survive long in the recipients’ 
circulation (33). Storage of PRP and PC at room temperature was reported to result in 
preserved viability during longer storage periods (34, 35), although a number of 
abnormal in-vitro parameters were shown at room-temperature, due to the higher 
metabolic activity. However, in-vivo studies that were performed of room-temperature 
stored platelets showed that they circulated longer in the recipients compared to chilled 
platelets (7 to 9 days vs. 2 to 4 days) and demonstrated better in-vivo function 
(sustained correction of bleeding time) after prolonged storage in the blood bank (36, 
37). 
The mechanisms for the rapid clearance of chilled platelets have emerged over the last 
decade. In brief, short-term cooling causes clustering of von Willebrand factor 
complexes on the platelet surface, rendering them susceptible to ingestion by hepatic 
macrophages that recognizes them via αM β2integrin receptors (38-40). Longer storage 
results in emergence of a different neoepitope recognized by hepatocyte 
asialoglycoproteinreceptors, leading to clearance. 
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Figure 5. Anaerobic and aerobic platelet metabolism (Hans Gulliksson) 
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With regard to the O2 supply, another important factor is the surface area of the storage 
container, available for gas exchange. When platelet units are stored on agitators, they 
shall be placed freely, and not be allowed to overlap or be covered to a great extent 
with labels or other material that diminishes O2diffusion. The suspension medium is 
also important, both with regard to buffering capacity and for the volume needed to 
move the platelets freely within the container. 
 
In 1960s, when PRP-PCs were stored, agitation was considered necessary for keeping 
platelets in suspension, allowing interruption only during transportation, according to 
AABB standards up to 24 hours as a maximum. Earlier studies showed a metabolic 
shift to glycolysis in platelet units when agitation was interrupted (43, 46-48). Agitation 
may ameliorate hypoxic or toxic metabolic microenvironments and facilitate O2 use by 
mitochondria, and may also prevent platelet contact-mediated metabolic changes. Later 
studies of PRP-PC and apheresis platelets suggest that agitation may be interrupted for 
up to 30 hours without significant negative effects on in-vitro parameters during storage 
of 5 days (49, 50). The form of agitation is also of importance, e.g. flatbed agitators 
appears to cause less damage than elliptical end-over-end and Ferris-wheel rotators (46, 
51).  
 
Prolonged storage of platelets at room temperature raises concerns for bacterial growth 
leading to septicemia, one of the main risks of transfusion (52). This has limited the 
storage time to 5 days in most countries, and in Germany to 4 days. In Sweden, a 
prolonged storage time to 7 days is allowed, provided bacterial testing has proved to be 
negative. 
Bacterial contamination derives from small amounts of bacteria entering via the 
phlebotomy site of the skin, due to insufficient disinfection, or due to disconnection of 
the closed system at any point of the preparation process. Detection of bacteria is 
complicated due to the fact that the initial inoculums are often very small (1-10 
CFU/ml). In the first hours, the bacteria can be neutralized by the antibacterial 
properties of blood, but if not, they can grow rapidly and reach high concentration at 
the end of the storage time. Therefore, the prevalence of bacteria detected will depend 
on the time of sampling, the volume sampled and the sensitivity of the method used 
(53, 54). Disinfection of the skin at the venipuncture site, and diversion of the first 
portion of blood has reduced the risk of bacterial contamination. However, additional 
screening of bacteria is essential (55). Different methods for bacterial screening have 
been developed, e.g. BacT/Alert system (bioMerieux, Durham, NC) and eBDS  
(PallCorp, East Hills, NY), and recently, a number of rapid tests intended for testing 
immediately prior to issue of the platelets (56, 57). 
 
1.5 PLATELET ADDITIVE SOLUTION 
Platelet additive solutions (PAS) have been developed since the 1990s, as a substitute 
for plasma. The main reasons for using PAS are to reduce the amount of plasma, which 
is an advantage in case of ABO-incompatibility, and to prevent adverse reactions and 
circulatory overload, retrieve plasma for fractionation, improve storage conditions and 
enable photochemical treatment in pathogen reduction (58). Extended storage of 
platelets is possible, due to the fact that aging of platelets at 22C is significantly slower 
than at 37°C.  
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Important factors for optimizing the storage conditions have proved to be 1) reducing 
the activation of platelets during whole blood collection, preparation and storage of 
platelets, 2) reducing the metabolic rate in terms of glucose consumption and lactate 
production, and 3) ensure an adequate supply of glucose in the storage medium 
throughout the storage period (59). 
The use of PAS makes it possible to add substances which affect platelets. A number of 
effects have been observed that can be assigned to different chemical compounds (59-
61). 
By reducing the activation of platelets and improving the metabolism and function by 
addition of key components in the storage medium, i.e. acetate, citrate, glucose, 
potassium and magnesium, it is possible to optimize platelet storage conditions.  
The compositions of different PASs are presented in Table 2. The first generations of 
PASs , PAS-II and PAS-III, was followed in the last decade by modifications of PAS-
III; called PAS-IIIM. 
 
Table 2. Composition of platelet additive solutions, including commercial names  
Ref: Blood component preparation, From benchtop to bedside, Ed. Blajchman, M., AABB Press 2011, Chapter 
Containers and Additive Solutions for Platelets, Gulliksson, H.  
 Plasmalyte 
A 
 
PAS- I SetoSol 
 
PAS-II 
T-Sol, 
SSP 
PAS-III 
InterSol 
CompoSol PAS-IIIM 
SSP+ 
Na Cl X X X X X X X 
KCl X X X - - X X 
MgCl2 X - X - - X X 
Na3-citrate - X X X X X X 
NaH2PO/ 
Na2HPO4 
- X X - X - X 
Na-acetate X - X X X X X 
Na-
gluconate 
X - - -  X - 
D-glucose - - X -  - - 
Maltose - - X -  - - 
D-mannitol - X X -  - - 
Plasmalyte A: Baxter International, Deerfield, IL, USA 
SetoSol: Terumo, Kanagawa, Japan 
T-Sol, InterSol : Fenwal, La Chatre, France 
SSP, SSP+: MacoPharma, Lille, France 
InterSol: Cerus, Concord, CA/Fenwal, Lake Zurich, IL, USA 
CompoSol: Fresenius Kabi, Bad Homburg, Germany 
 
The first generation of PAS was used in combination with the preparation of platelets 
from pooled buffy coats. The PAS consisted of a glucose-free medium combined with 
25% of plasma (62), and in-vitro and patient transfusion studies demonstrated a high 
quality. Further development were presented in subsequent studies (17, 63, 64). 
An investigation of storage of platelets in a pure saline medium, intended to serve as a 
reference to PAS, was performed 1992 (65), which unexpectedly proved to have 
similar in-vitro characteristics. This finding led to the introduction of saline as a PAS, 
in combination with 40% plasma, as a contributor of glucose and bicarbonate, intended 
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for storage of platelets from pooled BC for 5 days. This solution was used for several 
years, until it was replaced by second-generation PAS, PAS-II.  
PAS-II was composed of saline, with the addition of citrate at a reduced concentration 
compared to plasma, and addition of acetate, in subsequent steps, which allowed 
studies of the effects on platelet metabolism and quality during storage (65). PAS-II is 
still in clinical use in many countries, and was used for the preparation of the platelets 
at the time when the studies included in this thesis were performed. BC-PCs suspended 
in PAS-II are commonly pooled from 4-6 donors, with approx. 35-40% plasma carry-
over from the individual BCs, and approx. 60-65% PAS-II. 
 
PAS can be used in combination with preparation of apheresis platelets as well, where 
the storage medium consists of a combination of plasma (20-40%) and PAS (60-80%). 
Apheresis equipment are generally designed for the collection of a relatively larger 
volume of plasma as suspension medium for the platelets, but may be adjusted to 
collect a more concentrated platelet product in a smaller plasma volume, which 
subsequently can be mixed with PAS (66, 67). 
The PRP method is generally not combined with the use of PAS for routine 
preparation, although a study showing satisfactory preservation of platelet quality using 
this concept has been performed (68). 
 
Activation of platelets, caused by the different processing steps and storage has been 
long known (46, 69-71), measured by a number of different markers. In a comparative 
study of activation by three different preparation methods, activation of PRP-PC was 
found to be significantly higher than in BC-PC, whereas apheresis platelets showed 
intermediate activation (72). 
 
Presence of glucose during the storage period is crucial for platelet metabolism. Due to 
manufacturing difficulties (i.e.caramelization of glucose at neutral pH during the steam 
sterilization process), the majority of PAS formulas are non-glucose containing. The 
glucose is instead derived only from the plasma fraction, leading to low initial glucose 
levels of 5-10 mmol/L. Effects observed after depletion of glucose is rapid decrease of 
ATP and cessation of lactic acid production, leading to disintegration of platelets 
(73),(65). A slight correlation with in-vivo viability in terms of recovery below 50% of 
transfused platelets occurs at ATP-levels below 4.0 µmol/L/1011 platelets (74), levels 
often seen after depletion of glucose. In contrast to plasma, the fall in pH during storage 
of platelets in PAS will stop at significantly higher level than about 6.0, as a result of 
the limited amount of glucose. Because the buffering capacity of PAS generally is very 
limited compared to plasma, they are more susceptible to increased production of lactic 
acid (74-76). Units with high platelet concentration have an extra risk of glucose 
depletion at the end of the storage. Recently, studies have been performed of platelets 
stored in new formulas of PAS, where glucoses is connected to the PAS-container after 
the sterilization process, with in-vitro results similar to those in the plasma reference 
(77, 78). 
 
Acetate is used as a substrate for the aerobic platelet metabolism, which enters the 
tricarboxylic acid cycle and is further oxidized in the respiratory chain of the 
mitochondria (79, 80). End products are carbon dioxide and water. By formation of 
bicarbonate from the carbon dioxide produced by acetate, pH can be maintained at a 
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stable level during storage. The hydrogen ion necessary for bicarbonate production can 
be derived from lactic acid. In this way, the hydrogen ions produced by glycolysis are 
balanced by the removal of hydrogen ions by oxidation of acetate. Acetate present in 
PAS has also been shown to reduce the production of lactate and increase oxygen 
consumption by platelets (75, 76, 81, 82). 
 
Citrate is included mainly for anticoagulation, but there is some evidence that citrate 
and magnesium also modifies potassium efflux through the membrane (83). In addition, 
increased responsiveness to activating agents, i.e. ADP (84), and effects on glucose 
metabolism has been observed (82), suggesting that PAS should preferably should 
include low concentrations of citrate to avoid excessive lactate production and low pH. 
On the other hand, lactate production can be balanced by addition of acetate. A 
minimum level of 8 mmol/l of citrate seems to be required to prevent clotting problems  
(85). 
 
The effects of phosphate during storage are as a stimulant of glycolysis to produce 
lactate, and as a buffer to prevent fall in pH (75, 86). These two effects are 
counteracting and may neutralize each other.  
The presence of phosphate seems to be a critical factor to avoid low adenine nucleotide 
levels, and may have a significant influence on platelet metabolism when PASs are 
used. Studies reflecting this are included in Paper III. 
 
Magnesium, which is included in the latest generation of PASs, has been shown to have 
effects on platelet membrane function, platelet activation and the rate of glycolysis. 
Increased concentrations of extracellular magnesium ions significantly inhibits 
exposure of P-selectin, decreases binding of fibrinogen to ADP-activated platelets, and 
decreases agonist-induced aggregation (87, 88). 
Potassium, in combination with magnesium, has been shown to have a beneficial effect 
on platelet activation (89). 
 
1.6 LEUKOCYTE REDUCTION OF PLATELETS 
Leukocytes are generally regarded as contaminants in the blood components prepared 
from whole-blood, associated with a number of adverse effects. Leukocyte reducing 
filters with efficient removal of 4log10 or more has been developed, making it possible 
to prepare blood components with remaining leukocytes, with retaining a sufficient 
amount of the therapeutic blood elements (RBC or PLTs), according to current 
guidelines (13). 
During the 1990s the praxis of leukoreduction was widely spread, and many European 
countries implemented universal WBC reduction. In Sweden, universal leukoreduction 
is not mandatory, but is practiced at the majority of Blood Banks, and for 2011 all 
transfused platelets were leukocyte reduced (vs. approx 90% of transfused 
erythrocytes)(19). At our clinic, leukocyte reduction of all blood components was 
implemented from 1995. 
 
A number of clinical studies have documented the efficacy of leukocyte reduction in 
reducing the risk for febrile, non-hemolytic transfusion reactions (FNHTRs), 
refractoriness to platelet transfusion secondary to HLA alloimmunization, and 
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transmission of cytomegaloviruses (CMV). Other possible beneficial effects have been 
suggested, as reduced risk of transmission of cell-borne viruses, bacteria (90) and 
prions, prevention of adverse immunomodulatory effects (91-94) and decreasing the 
risk of TA-GVHD (95). 
 
Febrile non-hemolytic transfusion reactions (FNHTRs) after transfusion are reduced, as 
shown in several studies, with reported reaction rates from 0.33% to 0.37% to 0.18 
0.19% (p<0.001). Not only the leukocytes per se, but cytokines (IL-1, IL-6, IL-8, TNF-
α) secreted from WBC has been implicated for RBC (96-98) as well as platelets (99-
102), which makes pre-storage more advantageous than post-storage filtration, due to 
the benefits of early removal of the leukocytes (103). 
 
Platelets carry HLA class I antigens only, but in order to trigger an immune response, 
presence of HLA-class II presenting leukocytes (B-lymphocytes, monocytes, dendritic 
cells) are required. Removal of leukocytes from blood components to a level below  
5x 106/unit (104, 105) is therefore considered to prevent primary HLA 
alloimmunization and refractoriness to platelets (106-113). 
 
Reduced risk of transmission of infectious agents, i. e. viruses associated with subsets 
of leukocytes, as for cytomegalovirus (114) and sepsis (115, 116) have also been 
reported to be possible benefits. Universal leukocyte reduction was introduced in UK to 
reduce the risk of variant Creutzfeld-Jacob disease (vCJD) transmission by transfusion 
(117). 
 
Filtration to reduce leukocyte content of components is preferably performed 
prestorage, before they release breakdown products or cytokines (118), to enable 
process control, and to avoid the risks of adverse reactions caused by bed-side filtration 
(119-122).  
 
An alternative for the leukocyte reduction of separate blood components is filtration of 
whole blood, a procedure that allows removal from more than one blood component 
with one single filter. With the commonly used filters, the platelets are removed along 
with the leukocytes. The use of polyurethane for manufacturing of filters has allowed 
the development of filters that selectively remove leukocytes from whole blood, but 
allow the platelets to pass through the filter (123, 124). Blood components 
(erythrocytes and platelets) prepared after filtration of whole blood with this type of 
filter has been evaluated in Paper I. 
 
1.7 TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE 
Transfusion associated Graft versus host disease (TA-GVHD) is a complication to 
transfusion of immunocompetent cells, i e concomitant leukocytes, which involves 
fever, rash, gastrointestinal symptoms and bone marrow hypoplasia with pancytopenia. 
The symptoms appear 1-2 weeks after infusion, and have a high risk of mortality (80-
90%)(125-127). 
 
The condition was first described in mice, and requirements for GVHD were defined 
by Billingham as 1) the graft must contain immunologically competent cells, 2) the host 
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must possess important transplantation alloantigens which are lacking in the donor 
graft, so that the host appears foreign to the graft and therefore capable of stimulating it 
antigenically, and 3) the host must be incapable of mounting an effective 
immunological reaction against the graft (128). The first reports described TA-GVHD 
only in immunosuppressed individuals, following any blood component containing 
viable T-lymphocytes, but it has become evident that this condition can appear in 
immunocompetent recipients. The risk factors are transfusion from HLA -homozygous 
donors coincidentally haploidentical with the recipients (129, 130). This situation 
occurs infrequently when blood components are given from random donors, but is 
more common in populations with limited HLA-diversity, such as in Japan, where 
many cases of TA-GVHD has been described (131). Transfusing blood components 
from related donors, and platelets from HLA-matched donors, means a high risk of TA-
GVHD (132, 133). 
T-lymphocytes and NK-cells have been described to be involved in the pathogenesis, 
and cytokines are considered of importance in the process (126). 
 
The required dose of lymphocytes to induce TA-GVDH in mice is 107 (134). For 
humans, the dose has not been entirely defined, but case reports indicate that TA-
GVHD occurred after a dose as low as 104 lymphocytes/kg in a neonate (135). The 
viability which has been shown to decrease during refrigerated storage also has an 
influence on the risk. All cellular blood components convey a risk for TA-GVHD, 
which is described in susceptible patients after the transfusion of whole blood, red cells, 
platelets, granulocytes and fresh non-frozen plasma (136). There have been no reports 
of cases following the transfusion of cryoprecipitate or fractionated plasma products. 
Plasma that has been frozen is generally not considered as giving risk for TA-GVHD, 
although a single case has been reported in a severely T-cell immunodeficient patient 
(137). 
 
Based on these data, the major indications for prevention of TA-GVHD are for patients 
undergoing transplantation with hematopoietic stem cells, Hodgkin lymphoma (due to 
defective T-cell function), patients treated with fludarabine (purine analogue), 
intrauterine transfusions and in transfusions to premature neonates, and transfusions 
from relatives or HLA-matched donors. 
 
No specific treatment for TA-GVHD has been proven to be successful in reversing an 
established extensive TA-GVHD, so the focus is instead on prevention. The current use 
of leukocyte-depleting filters achieves an amount of <106 leukocytes/unit. This level 
has been reported to reduce the risk of TA-GVHD substantially (95) but cannot be 
considered as a safe single method to protect from TA-GVHD, as the probable dose of 
lymphocytes to induce a risk for TA-GVHD is below that limit (138).  
Gamma irradiation was the first method to be practiced, and is still the most prevalent 
method for prevention of TA-GVHD. Later, blood irradiation equipment using X-ray 
technology was made available for Blood Transfusion Services.  
Methods to inactivate viral and bacterial pathogens in blood components have proved 
to be an alternative to irradiation for prevention of TA-GVHD. Novel psoralens, e.g. 
S59; amotosalen (INTERCEPT) has been synthesized to enhance viral and bacterial 
inactivation without compromising the platelet function. In a study performed by Grass 
et al (139), T-lymphocytes were shown to be exquisitely sensitive to S59. They were 
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inactivated to an undetectable level by a 3000-fold lower dose than acquired for the 
inactivation of pathogens. Other pathogen reduction systems, as riboflavin (Mirasol) 
has also been shown to inactivate lymphocytes to a degree which makes them suitable 
for TA-GVHD-prevention (140).  
 
1.8 IRRADIATION OF PLATELETS 
Irradiation, either gamma or X-ray, produces ionizations and free radicals that damage 
cellular DNA, thereby precluding replication required to allow the development of TA-
GVHD. Specifically, it prevents T-cell replication following a dose sufficient to cross-
link or damage T-cell DNA. Because erythrocytes and platelets are anucleate cells 
without DNA, doses sufficient to inactivate T cells does not seriously affect erythrocyte 
or platelet function (141). The irradiation devices display significant variation in dose 
distribution throughout the irradiated volume, e.g. 30% variation along the central axis 
and 35% between the periphery and the centre of the canister. Due to the uneven 
distribution of irradiation observed, the recommendation is to deliver a central dose 
high enough to ensure that the minimum dose also is sufficient to inactivate 
lymphocytes, the minimum dose required considered to be 25 Gy. This level is based 
on data from a study where red cell units were exposed to increasing doses of radiation, 
showing that doses of 15 Gy and 20 Gy abrogated most, but not all, clonal T-
lymphocyte proliferation, whereas irradiation with 25 Gy abolished cell growth (142). 
According to European guidelines (13), the recommended dose is 25-50 Gy in any part 
of the irradiated canister. 
 
Gamma irradiation equipment contains a radioactive source, either cesium (137Cs) or 
cobalt (60Co), that undergoes a constant rate of decay. Equipment with cesium 137 is 
the most widely used, due to its longer half-life (30 vs. 5.2 years). A longer half life is 
beneficial both for less frequent dosage adjustments as well as longer usable life of the 
source. Irradiators must be dose mapped annually, and dose adjustment at least 
annually for cesium sources, or quarterly for cobalt sources (142). Cesium irradiators 
typically allow 1-4 blood units to be irradiated at the same time. When loading the 
canister, the operator is protected by a lead shield, and the canister is rotated into 
position to be exposed to the cesium sources in the interior of the equipment. An 
irradiation indicator is often applied on the blood components, to indicate effective 
irradiation of each batch. Cesium is a highly reactive compound, hence the use is 
strictly regulated. High demands on security regarding the use of high activity sealed 
radioactive sources (HASS), concerning access, training, control of absorbed dose and 
leakage, and disposal are laid down in legislation (143). However, concerns about the 
safety, and reported dispersal accidents (144) from disposed devices has encouraged the 
development of an alternative to cesium irradiators.  
 
In recent decades, X-ray equipment for blood components has become available, that 
uses 1-2 X-ray sources. In terms of safety, it is an advantage that X-rays are emitted 
only during irradiation cycles, and can be disposed of as any electronical equipment. 
However, these devices are considered to have higher cost for maintenance and part 
replacement costs, such as X-ray bulbs, which burn out periodically and need 
replacement. Control of absorbed dose is recommended at least 2 times per year, and 
control of radiation leakage during operation shall be performed regularly. Typically,  
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1-3 blood units can be placed in a canister and irradiated in one cycle. The use of 
irradiation indicators adjusted for X-rays are recommended. 
 
Irradiation affects cellular membranes and results in potassium leakage in erythrocytes, 
which limits the storage after irradiation (145). However, limitation of storage time for 
irradiated platelet is not considered to be required, as platelets have a shorter shelf-life 
than erythrocytes. 
 
A number of studies have been done to assess the effects of gamma irradiation of 
platelets, including in-vitro parameters and in-vivo recovery and survival, the majority 
indicating that irradiation does not compromise the quality (146-152). According to 
guidelines in UK, platelets can be irradiated with 20-50 Gy at any time during storage 
and thereafter be stored up to their normal shelf life after collection (153). Prestorage 
irradiation is preferred at many centers, mainly of logistic reasons, in order to have 
platelets readily accessible, which is especially important in emergency situations. 
 
The studies outlined in paper IV address the effects of prestorage irradiation of platelets 
during storage for 7 days, which confirms the results from previous studies. In addition, 
evaluation of effects of X-ray irradiated platelets was performed, with similar results, 
indicating that X-ray do not compromise the in-vitro quality of platelets during storage 
for 7 days. 
 
1.9 QUALITY ASSESSMENT OF PLATELETS 
When introducing new methods for preparation and storage of platelets, assessment of 
the impact of platelets is essential.  
 
In transfusion medicine, the main application of in vitro tests has been to determine 
platelet quality in PCs. The major disadvantage is that it somewhat unclear how these 
results translate to platelet recovery and survival in vivo after transfusion. However, the 
in vitro data provide a level of reassurance prior to the clinical use of the component, 
whereas poor in vitro performance would be a major cause of concern and require 
further studied before introducing the method in routine production. 
The hierarchy of studies in validation of major changes of methods are 1) in vitro tests 
2) recovery and survival in healthy volunteers 3) count increment studies in 
thrombocytopenic patients, and 4) an assessment of haemostasis (measurement of 
bleeding) in thrombocytopenic patients (154). 
Swirling, a light scattering phenomenon attributable to the discoid shape of non-
activated platelets, is a morphological test which is non-invasive and easy to perform, 
and is used as a pre-issue test at many centers. Platelet concentrates that fail to swirl 
have pH below 6.4 or above 7.6 in most, but not all, cases (155). 
 
For the metabolic parameters, it is known that pH values below 6.0-6.2 are associated 
with poor in vivo recovery (35, 156). The relationship between high pH and in vivo 
viability is less clear. Some studies demonstrate a loss of recovery in vivo at pH values 
above 7.2-7.7 (157, 158), whereas others show that PC with a pH up to 7.6 did not 
result in loss of in vitro function or poor in vivo recovery (159). 
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Extent of shape change (ESC) which is a measurement of the shape change induced by 
ADP by an aggregometer has been shown to correlate well with recovery in vivo (74). 
Hypotonic shock response (HSR), which is the ability of platelets to extrude water after 
the swelling caused by a hypotonic environment, is measured by an aggregometer. This 
parameter was shown to correlate to some degree with in vivo viability (74), although 
later studies could not confirm this (160). It was also shown by Holme et al, that ATP 
levels below 4.0µmol/1011PLT causes loss of in vivo viability (73). 
Examples of substances released from α-granules, e.g. RANTES and PF4, are 
measured both as markers of activation, and for their purported role in allergic 
transfusion reactions (161). 
 
In addition, expression of platelet glycoproteins involved in adhesion and aggregation 
(e.g. GpIb, GPIIa/IIIb), expression of activation markers (CD62P, CD63, CD40L), 
exposure of negatively charged phospholipids and formation of platelet-derived 
microparticles can all be studied during storage with flow cytometry using a number of 
commercial reagents (154). 
 
Different in vitro test indicating apoptotic changes have also emerged, e.g. 
depolarization of mitochondrial membrane potential and microparticle generation 
(162). However, apoptotic changes during storage of platelets seem to play a role only 
in case of buffer exhaustion with consequent deleterious pH decrements (163). 
 
The survival and recovery of autologous radiolabelled platelets transfused to healthy 
volunteers are considered to be the best indicators of PC quality, although the methods 
are technically demanding and laborious. A standard has been proposed by Murphy et 
al (164) that the mean recovery should be >66% and survival >50% of fresh platelets. 
Recently, a multicolor flow cytometry method was developed for simultaneous studies 
of recovery, survival, and function of transfused PLTs was described as an alternative 
method (165). 
In clinical studies measurements of platelet count increments (CI) at 1hour and 24 
hours post transfusion are used to evaluate the effect of transfusions. A corrected count 
increment (CCI), takes the transfused dose and body surface of the patients into 
account. To agree with Cardigan et al (154), the platelet count provides little 
information of the functionality of the cells, but it is clearly a prerequisite for platelets 
to be able to circulate in order to function. Although, it may be argued that in the setting 
of therapeutic platelet transfusion (i.e. to stop a bleeding) the platelets, although well-
functioning may not lead to a high increment, as the platelets are engaged in the 
hemostatic process, rather than circulating. 
 
Another optional analysis, is assessment of platelet function in the context of clot 
formation, i.e. by use of thrombelastography (TEG, ROTEM)(166). Studies have 
shown that clot strength is minimally affected after storage of PC for five days (166, 
167). A similar method described by Tynngård et al, is free oscillation rheometry (168, 
169). 
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1.10 PLATELETS FOR TRANSFUSION 
Platelet transfusions were shown to reduce mortality from hemorrhage already in 1960s 
(170), and the utilization has since increased steadily, to become a prerequisite for 
treatment in many clinical settings. Stroncek reported in 2007 that 2 million platelets 
were transfused in USA and 2.9 million in Europe (171). In Sweden, the demand for 
platelets is increasing every year, and during 2011, 50.000 units were transfused (19), 
or 5.3/1000 inhabitants, which is an increase of approx. 60% compared to 2000.  
 
In order to meet the demands, hospital blood banks need to have platelets in store, 
readily accessible in acute situations. Due to the relatively short shelf-life of 5 -7 days, 
it requires careful planning in order to balance outdating and shortage.  
To ensure proper storage conditions, platelets are stored on flat-bed shakers in 
incubators with regulated temperature. Continuous surveillance of temperature, and a 
system for alert when the temperature is out of range, needs to be in place. Conditions 
during transport of platelets should be validated, and monitored at regular intervals. 
 
Regular quality controls with regard to cell content (platelets, leukocytes) and pH at the 
end of storage shall be performed, to ensure that requirements by current standards are 
met (13).  
Although bacterial screening is mandatory only for prolonged storage of 7 days, it is 
performed on an increasing number of platelet in Sweden (19). Previously, at the time 
the studies in this thesis were performed, aerobic and anaerobic bacterial cultures were 
done, of approx 20% of platelets. At present, eBDS is performed, of approx 66% of 
platelets. 
 
In Sweden 2011, all platelets were leukocyte reduced, and approx. 55% were irradiated. 
At our clinic, all blood components are leukocyte reduced. In addition, all platelets are 
irradiated, a praxis that was introduced due to the fact that the group of patients that 
need platelets overlap to a great extent the group that needs irradiated blood 
components. This fact made it an advantage from a logistic point of view. 
 
Coding and labeling of blood components are necessary to ensure traceability, from the 
donors to the recipient, and also facilitates records of all sequential steps in preparation. 
With regard to platelets, a change of component code is made and recorded in 
connection with pooling of buffy coats to a platelet concentrate, leukoreduction, 
irradiation and bacterial screening etc. 
 
Statistics from the Swedish Society of Transfusion Medicine (19) regarding number of 
platelet concentrates transfused, bacterial screening performed and positive bacterial 
cultures in Sweden 2000-2011 are shown in Figures 6-8. 
 
 
 
 
 
 
 
Totalt antal transfunderade trombocytdoser 
per 1000 invånare och år 2000‐2011
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
buffy‐coat 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.4
trombocytaferes 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.2
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Kontroll av bakterieförekomst i trombocytenheter
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Antal doser som transfunderats 30606,0 31532,0 33882,0 32531,0 35121,0 33174,0 35195,0 38091,0 38941,0 43256,0 42817,0 49866,0
Antal doser som kontrollerats 3252,0 5771,0 7166,0 8780,0 9253,0 8106,0 13328,0 13778,0 13261,0 15901,0 15613,0 21723,0
Patogen inaktiverade 5189,0 8537
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Figure 6. Total number of transfused PC per 1000 inhabitants in Sweden 2000-2011
Figure 7. Bacterial screening of PC 2000-2011
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                                                                                 Figure 8. Number of positive bacterial cultures of PC 2000-2011 
 
 
                                                 Figures 6-8. Marja-Kaisa Auvinen, based on Statistics from Swedish Society of Blood Transfusion 2011. 
Positiva bakterieodlingar i trombocytenheter
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Antal positiva (bekräftat) 10 20 45 33 8 21 15 18 16 18 13 8
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Figure 8. Number of positive bacterial cultures of PC 2000-2011
Figures 6-8. Marja-Kaisa Auvinen, based on statistics from Swedish Society of Transfusion Medcine 
2011
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2 AIMS 
 
The overall aim is to gain increased knowledge of the impact of new equipment and 
new preparation techniques for blood component preparation, with special focus on 
improving quality and safety of platelets intended for transfusion. 
 
 
The specific aims are: 
 
Paper I – to study the impact of a novel platelet saving whole blood filter on prepared 
erythrocytes and platelet concentrates from pooled leukocyte reduced buffy coats 
during storage. 
 
Paper II – to study the use of novel automated equipment for preparation of pooled 
buffy coats, with special attention paid to reduced platelet count variation due to  
selection of buffy coats based on donor platelet counts.  
 
Paper III – to study the impact of different suspension media on the quality of platelets 
from pooled buffy coats and from apheresis, with focus on the effects of phosphate. 
 
Paper IV – to study the impact of irradiation on different platelet preparations using 
both cesium radioactive source (gamma irradiation) and the novel X-ray irradiation 
equipment.  
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3 MATERIAL AND METHODS 
 
3.1 PREPARATION AND STORAGE OF PLATELETS 
Paper I 
Whole blood was connected sterilely to a leukocyte depletion filter (prototypes, 
WBFSP, Terumo) made of multiple polyurethane sheets which allow penetration of 
platelets due to the characteristics of the plastic material (172). Filtration was 
immediately followed by centrifugation at 2700 g for 10 minutes at 22°C (Beckman 
J6MI centrifuge, Beckman instruments, Palo Alto, California, USA) and separation into 
RBCs, plasma and leukocyte-reduced BC using automated equipment (T-ACE, 
Terumo) and channeled side-flow quadruple bags (supplied by Terumo, made of PVC 
with DEHP as plasticizer). This is a variation of the top-and-bottom blood bag system. 
RBCs were suspended in 100 mL of SAGMAN solution. The leukocyte-reduced BCs 
were kept at room temperature overnight, and 5 BCs were pooled the following day by 
sterile connection into a pooling bag (600 mL, JMS, Singapore). The pooled BCs was 
rinsed with 300 ml platelet additive solution (T-Sol, Baxter, La Châtre, France) and 
centrifuged, thereafter the platelet-rich supernatant was transferred to a storage 
container (1000 mL, UPX-80 JMS, Singapore). The ratio of plasma: T-Sol in the 
platelet suspension medium was approximately 35:65. Platelets were compared to 
platelets prepared manually from pooled buffy coats with the same suspension medium. 
Platelets were kept at flatbed agitators at 20-24C during storage for 7 days, and samples 
were taken at D1, D3, D5 and D7. 
 
 
Paper II 
Whole blood (450±45 mL) was drawn from healthy donors, in blood container systems 
containing 63 mL of standard CPD-solution as anticoagulant. The whole blood 
containers were kept at room temperature (20º-24ºC) by cooling plates, and centrifuged 
at 2700g for 10 minutes at 22°C within 8 hours of collection. Centrifugation was 
immediately followed by separation into RBC, plasma and BC, using automated 
equipment. The BC, were kept overnight without agitation at room temperature (20º-
24ºC). In all experiments, the preparation of BC for platelets was similar. 
In a first sequence, ABO-identical BC (5-6/pool) and PAS are pooled in a ring-shaped 
container. This step includes washing of the BC containers with PAS. In a second 
sequence, the contents of the ring-shaped pooling container are mixed and centrifuged, 
followed by transfer of the platelet-rich supernatant into a container placed in the center 
of the centrifuge. In the first design, the leukocytes in the platelet-rich supernatant was 
reduced by filtration after removal of the disposable from the equipment (used in 
experiments 1-3). In the next design, a leukocyte reduction filter and platelet storage 
container was integrated in the system (used in experiments 4-6). The suspension 
medium was a combination of platelet additive solution (approx. 65%), together with 
plasma carry-over (approx. 35%) from the individual buffy coats. 
Platelets were kept at flatbed agitators at 20-24°C during storage for 7 days. 
Bacterial cultures were performed on approx. 20% of all platelets, according to the 
standard routines on samples taken at the completion of component preparation. 
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Experiment 1: Paired in vitro study of BC-PCs (n=6) from 6 BC, suspended in a mix of 
CPD plasma carry-over from the individual buffy coats together with PAS-II, with the 
proportions plasma:PAS-II 35%:65%, where automated (OrbiSac) and manual 
preparation was compared. 
 
Experiment 2: Automated routine preparation of PCs from pools of 6 BCs (n=409), for 
clinical use. Platelet count was determined in all units, and the recovery of platelets in 
some of the units (n=82).  
 
Experiment 3: Standardization of platelet content 
PC (n=98) intended for clinical use, prepared from 6 ABO-identical BC by the OrbiSac 
system prepared as described above. The selection of BC for pooling was made 
manually, on basis of the platelet concentration of the individual blood donors. Platelet 
count was determined in all units 
 
Experiment 4: Paired in vitro study of PC from pools of 6 BC (n=6) using the OrbiSac 
system with an integrated leukocyte filter comparing two different storage containers, a 
Gambro ELP (Gambro BCT, Lakewood, CO, USA) and UPX-80 (JMS, Singapore) 
storage container.  
 
Experiment 5: PC (n=611) intended for clinical use were prepared from 6 ABO-
identical BC by using the OrbiSac system with an integrated leukocyte reduction filter. 
The platelet count was determined in all units, and the recovery of platelets in some of 
the units (n=24).  
 
Experiment 6: Standardization of platelet content and reduction of number of BC in the 
pools 
PC (n=292) intended for clinical use were prepared with the OrbiSac system that 
included an integrated leukocyte reduction filter, where pools of five ABO-identical BC 
were combined, using a computer program (“Orbiselect”). The platelet count was 
determined in all PC, and the variation in the platelet content was compared to that in 
PC prepared after pooling of the BC at random. The recovery of platelets was 
determined in a smaller number (n=36) of PC. 
 
 
Paper III 
The platelet preparations that are evaluated in this study are from pooled buffy coats 
and from apheresis, suspended in a mix of plasma and platelet additive solutions, one 
without phosphate (PAS-II) and one with phosphate (PASIII), or solely in plasma. All 
units were leukocyte reduced. Platelets were kept at flatbed agitators at 20-24°C during 
storage for 7 days. 
 
Experiment 1: Paired study of platelets (n=6) prepared from 5-6 pooled buffy coats, 
suspended in a mix of CPD plasma and two different PASs (PAS-II and PAS-III), with 
the proportions plasma:PAS 35%:65%. Preparation was done by manual methods. 
 
Experiment 2: Single study of platelets (n=8) prepared from 5-6 pooled buffy coats, 
suspended solely in CPD plasma.  
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Experiment 3: Paired study of platelets (n=7) prepared from 5-6 pooled buffy coats, 
suspended in a mix of CPD plasma and two different PASs (PAS-II, PAS-III), and 
addition of glucose, with proportions plasma: PAS: 20%:80%. Preparation was done by 
manual methods. 
 
Experiment 4: Two apheresis systems were tested in two parallel studies. 
Paired study of apheresis platelets (n=6) from single donors were collected with 
Amicus (Baxter), where platelets suspended in a mix of ACD plasma and PAS II, with 
proportions plasma: PAS 35%:65% were compared to apheresis platelets suspended 
solely in ACD-plasma.  
Paired study of apheresis platelets (n=6) from single donors collected with Spectra 
(Cobe) , where platelets suspended in a mix of ACD plasma and PAS II, with 
proportions plasma: PAS 35%:65% were compared to apheresis platelets suspended 
solely in ACD-plasma.  
The apheresis collections were performed according to company equipment manuals. 
 
Experiment 5: Apheresis platelets from single donors (n=14) were collected in three 
different blood cell separators: Spectra (Cobe), Excel (Dideco) and CS3000 Plus 
(Baxter), and suspended in a mix of ACD plasma and two different PASs (PASII, 
PASIII), with proportions plasma: PAS 35%:65%. The apheresis collections were 
performed according to company equipment manuals. 
 
 
Paper IV 
Apheresis platelets: 
Platelets from healthy donors was drawn by apheresis equipment TRIMA (Caridian 
BCT, Inc, Lakewood, CO, USA) with in-process leukoreduction (LRS-chamber), and 
suspended in ACD-plasma from the donor. Initially, apheresis platelets suspended in 
40% plasma and 60% PAS were prepared, but later replaced by apheresis platelets in 
100% plasma.  
 
Platelets from pooled buffy coats: 
Whole blood (450±45 mL) was drawn from healthy donors, containing 63 mL of 
standard CPD-solution as anticoagulant. The whole blood containers were kept at room 
temperature (20-24ºC) by cooling plates, and centrifuged at 2700g for 10 minutes at 
22°C within 8 hours of collection. Centrifugation was immediately followed by 
separation into red blood cells (RBC), plasma and buffy coats BC, using automated 
equipment (T-ACE, Terumo or Optipress, Fenwal). BC, consisting of approx. 20 mL of 
blood cells and 25 mL of plasma, were kept overnight without agitation at room 
temperature (20-24ºC). BC-PC was prepared by the OrbiSac system (Caridian BCT, 
Inc, Lakewood, CO, USA). Five to six BC and 300 ml of PAS-II (T-Sol, Baxter) were 
used per platelet unit prepared, with 35% plasma from plasma carry-over from BC and 
65% PAS. The platelet units were kept on a flat bed agitator  in a temperature-
controlled cabinet (20-24ºC). 
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The different platelet preparation techniques and the two different irradiation 
equipments have been evaluated, in paired studies: 
Irradiation equipment with cesium as radioactive source: 
Platelets prepared by apheresis, suspended in T-Sol/plasma, were divided into two 
equal parts (n=6), of which one part was irradiated the day of preparation, and the other 
half stored as non-irradiated reference.  
Platelets prepared from pooled buffy coats, suspended in T-Sol/plasma, were pooled 
and subsequently divided into two equal parts (n=6), of which one part was irradiated 
the day of preparation, and the other half stored as non-irradiated reference. 
 
Irradiation with X-ray equipment: 
Platelets prepared by apheresis, suspended in T-Sol/plasma, were divided into two 
equal parts (n=6), of which one part was irradiated the day of preparation, and the other 
half stored as non-irradiated reference. 
Platelets prepared by apheresis, suspended in plasma, were divided into two equal parts 
(n=6), of which one part was irradiated the day of preparation, and the other half stored 
as non-irradiated reference. 
 
3.2 BACTERIAL SCREENING OF PLATELETS 
Aerobic and anaerobic bacterial cultures on samples from the platelet units (by sterile 
docking of a sampling pouch) were performed at the Microbiological laboratory, 
Södersjukhuset, Huddinge University Hospital and Karolinska University Hospital. 
 
3.3 IRRADIATION OF PLATELETS 
Paper I-III 
The platelets described in these studies were not irradiated. At the time of these studies, 
irradiation was performed post storage, on demand, before issue of the platelets. 
 
Paper IV 
Irradiation was performed immediately after preparation, either by Gammacell Elan 
3000 (MDS Nordion, Canada) with cesium-137 as radioactive source, or by X-ray 
equipment Raycell (Best Theratronics, former MDS Nordion, Canada). Irradiation 
indicator, i.e. labels which by physical change indicates that irradiation has been 
performed, was used. The absorbed dose was minimum 25 Gy and maximum 50 Gy in 
any part of the container, according to European regulations (13). The absorbed dose 
are controlled once (Gammacell Elan 3000) or twice (Raycell) yearly, by dosimetry 
performed by MD Anderson Cancer Centre, University of Texas, Houston, USA. 
 
3.4 IN VITRO ANALYSIS 
3.4.1 Cellular and metabolic parameters 
Paper I-III 
Cell counts in the in vitro erythrocyte and platelet storage studies were made using an 
automated cell counter (AC 920, Swelab Instruments, Stockholm, Sweden). 
Residual white blood cells in the PC were counted, using a Nageotte chamber (173).  
For the determination of pH, pO2, pCO2, and bicarbonate, a pH/blood gas analyzer was 
used (Model 1610, Instrumentation Laboratory, Lexington, MA, USA). Glucose and 
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lactate were analyzed by spectrophotometry, using commercial kits ( Cat Nos 16 and 
826, Sigma Chemical Co. St.Louis, MO, USA). A firefly luciferase assay (65) was used 
for the determination of adenosine triphosphate and total adenosine nucleotides. The 
extracellular potassium concentration (Paper I) was analyzed in the department of 
Clinical Chemistry at Södersjukhuset, using a Hitachi 917 equipment (Hitachi, Tokyo, 
Japan). Hemolysis (paper I) was determined by a photo spectrometric method (Varian 
DMS 100, wavelength 540 nm). The method for measuring adenylate kinase 
(ATP:AMP phosphotransferase, EC 2.7.4.3) as described by Olsson et al (174) was 
used as a marker of platelet disintegration. In paper II, lactate dehydrogenase, using 
enzymatic techniques was introduced as another marker of platelet disintegration. 
 
Paper IV 
Cell counts in the in vitro platelet storage studies were made by an automated cell 
counter (Medonic CA620, Boule Instruments, Stockholm, Sweden).  
Residual white blood cell count (WBC) on day 1 was determined with a Nageotte 
chamber and a microscope (Zeiss, standard, Chester, VA, USA)(173). For the 
determination of pH, pCO2, pO2, bicarbonate, glucose and lactate a pH/blood gas 
analyzer was used (ABL 800, Radiometer, Copenhagen, Denmark). Bicarbonate 
(mmol L) was calculated from pH and CO2 partial pressure measurements. The 
extracellular lactate dehydrogenase (LDH) activity (% of total), a marker for 
disintegration of PLTs, was measured with a spectrophotometric method (Sigma 
Aldrich kit 063K6003;St Louis, MO, USA; Spectrophotometer Jenway 6500, 
Staffordshire, UK)(175). 
Analysis of the chemokines PF-4 and RANTES was performed with commercial kits in 
accordance with the manufacturer´s recommendations (Quantikine R&D system, 
Abingdon, UK for RANTES, and Asserachrom Diagnostica Stago SA, Asnières, 
France for PG4) described in detail in earlier work (42). 
 
3.4.2 Functional parameters 
Paper IV 
Hypotonic shock response reactivity (HSR) as well as the extent of shape change (ESC) 
measurements was performed using a dedicated microprocessor based instrument (SPA 
2000, Chronolog, Havertown, PA, USA) with the modifications of these tests described 
by Van den Broeke et al (176). The total adenosine triphosphate (ATP) concentration, 
was determined with a Luminometer (Orion Microplate Luminometer, Berthold 
Detection Systems GmbH, Pforzheim, Germany) on the basis of principles described 
by Lundin (177). 
 
3.5 STATISTICAL ANALYSIS 
Mean and standard deviations are given. Groups are compared on a one-to-one basis, in 
paper I, II and III using a two-tailed t-test for a two-sample test, with statistically 
different significance at p<0.05. In paper IV, a repeated measure ANOVA including 
post hoc test Bonferroni´s adjustment was performed, with“Days” as the repeated 
factor and “Group” as a between factor. The P-value represents the difference between 
groups at specific time points and was considered statistically significant at P<0.001. 
The analyses were carried out using the Statistica software, version 9 StatSoft, Inc 
1984-2007 (SPSS, Chicago, IL, USA). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
The practice of leukocyte reduction of blood components raised a concern about the 
significant numbers of cells that were lost in these processes, for erythrocytes often 10-
20% in the BC and additionally 10-15% in the leukocyte depletion filter, in total 20-
35%. With a whole-blood filter, which results in two leukocyte depleted blood 
components, i.e. RBCs and plasma, these losses can be reduced. However, available 
whole blood filters also remove platelets, which imply that there will be no alternative 
to the apheresis technique for the supply of platelet concentrates (PCs). 
 
In the present study, a leukocyte depletion filter is evaluated that removes WBCs but 
not platelets, and produce three different leukocyte depleted blood components, RBCs, 
plasma, but also PCs. PCs could be prepared in a second step from either platelet-rich-
plasma with no further loss of red cells, or alternatively after centrifugation from the 
thin buffy coat (BC) layer formed by platelets which have passed through the leukocyte 
filter. With regard to the composition of BCs, there is no need to go deep down into the 
red cell layer to remove granulocytes, since these cells are already removed by the 
whole blood filter. What would be needed is a stable blood cell layer to save and to 
transfer platelets for preparation of PCs. By this, it would be possible to reduce the 
amount of blood cells in the BCs and, consequently, also reduce the loss of red cells in 
the BC removal step.  
 
The present study is based on filtration of 30 whole blood units using prototype filters, 
primarily to investigate the efficacy of white blood cell removal, loss of red cells and 
platelets and secondly, to investigate RBCs and PCs during storage. 
The leukocyte removal is highly effective resulting in a residual WBC count well 
below the recommended limit (i e in Europe 1x106 WBC per transfused unit)(13). The 
recovery of 90% of red cells after filtration of whole blood is encouraging. This 
reduction is consistent with loss of volume in filter and tubing. In the case of RBCs, we 
recovered 73% of the red blood cells in the whole blood. For platelets, 81% of the cells 
are left after whole blood filtration, indicating loss of volume as well as trapping in the 
filter. In our study, 66% of the original platelet count in whole blood was recovered in 
the PCs.  
 
The basic in vitro investigation of storage of RBCs (n=10; randomly selected) for 42 
days suggest that pH and concentration of adenine nucleotides are similar to standard 
RBCs with BC removed and stored in SAGMAN solution, with the exception of day 
42, when ATP levels were significantly higher, and the degree of hemolysis, which is 
stable at a level of about 0.2% throughout storage, in whole blood filtered units. 
Generally, hemolysis increases gradually during storage of RBCs. The difference 
observed may be associated with the early removal of WBCs in the present study. 
Previous studies indicate that red cells stored in the presence of WBC undergo 
increased hemolysis, since proteases discharged primarily from granulocytes at 
disintegration have a potent hemolytic effect (178). The levels of extracellular 
potassium in whole blood filtered units during storage are similar to those in previously 
described studies (179, 180). 
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Six units of PCs were prepared from BCs and platelet metabolism were studied during 
storage. In the in vitro study of PCs during 7-day storage, significantly higher values in 
whole blood filtered units compared with reference units were found for concentration 
of glucose and lactate. These differences observed from day 1 throughout storage may 
be explained by differences in storage time of whole blood and BCs preceding PC 
preparation associated with the different preparation techniques. However, no effects 
on adenine nucleotide levels were found, suggesting stable storage conditions and 
unaffected energy generation by platelet metabolism. The additional occasional 
differences (pH, pO2, pCO2, bicarbonate and adenylate kinase) are probably of no 
importance. 
 
The conclusions from this basic preliminary evaluation of the platelet-saving in-line 
whole blood leukocyte depletion filter are that the results with regard to leukocyte 
removal, recovery of red cells and platelets as well as in vitro storage investigations are 
encouraging. This new type of filter offers a possibility of combining the efficacy of 
whole blood filtration with preparation of PCs from conventional whole blood units, 
and may simplify blood component preparation.  
 
 
Our basic study was later followed up by a multicenter study (123) with a whole-blood 
filter of polyurethane, the surface of which shows high biocompatibility and very low 
attraction for platelets. Leukocytes were removed by the mechanism of sieving. The 
filter (Imuflex WB-SP, Terumo) had been registered in Europe, allowing clinical use of 
the blood components prepared. 
Average platelet recovery from WB to PCs of 62±10% compares well with previously 
published data on methods ensuring high platelet harvests (16, 181). Also, median Hb 
recovery of 81% compares favorably to reported recoveries in BC-removed and 
subsequently filtered erythrocyte concentrates (182-184), and preserved FVIII in 
plasma components. 
 
Although the encouraging results with the prototype and Imuflex filter, this has not 
been pursued so far at our clinic, the main reason being the high costs of the filter. 
 
4.2 PAPER II 
Preparation of pooled buffy coat platelets, which until then was done by manual 
methods, was in this study performed with the new OrbiSac equipment. This equipment 
allows automation of the crucial preparation steps, i.e. rinsing of the buffy coat bags, 
and extraction of the platelet-rich supernatant into the final storage container. However, 
some of the preparation steps, as sterile docking of the buffy coat, and disconnecting 
the empty bags after rinsing, are performed manually. In the first period, the platelets 
were leukoreduced after completion of the OrbiSac process, by passing them through a 
leukoreduction filter. Later, a leukoreduction filter was integrated in the OrbiSac 
disposable kit, which enabled in-process filtration. 
 
Another aspect of the preparation process addressed in this paper is standardization of 
platelet content in the final product. This is achieved by two means, i.e. selection of 
buffy coats for pooling, and by the higher reproducibility in processing when the 
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crucial processing steps (rinsing, centrifugation, extraction of platelet rich supernatant) 
are being automated. In contrast, when all processing steps are performed manually, the 
recovery of platelets is to a great extent dependent on the skill of the technicians. The 
selection of buffy coats for pooling was also a subject for investigation, with the aim to 
standardize the final platelet content. The platelet concentration in samples from the 
donor proved to be a useful tool to diminish the variability in final platelet counts, 
based on the assumption that the yield of platelets in the buffy coat from donors with 
high concentration would be higher, which is true provided that whole blood separation 
has been optimal.  
 
Later, by including an in-process leukoreduction filter, which minimized the extra 
workload, the process was made more efficient. We also evaluated different storage 
containers, with regards to quality during storage over 7 days. 
 
Taken together, the results show that standardization was achieved, the overall process 
resulted in platelets with high and stable recovery, with in vitro parameters indicating 
preserved viability during the storage period of 7 days. Bacterial cultures were 
performed on a large number of platelets, of which all were negative. 
 
The OrbiSac system was introduced for routine preparation at our clinic as a result of 
this evaluation, and has been in use since then. Over the years, as the demand for 
platelets has increased, additional devices have been installed. 
 
4.3 PAPER III 
Based on earlier studies of PAS regarding the impact of citrate and acetate (76, 79, 80, 
82), a PAS containing 10 mmol/L of citrate and 30 mmol/L of acetate, called PAS-II, 
was composed. PAS-II was introduced for storage of platelets prepared from pooled 
buffy coats, and for apheresis platelets at our clinic. BC-PC were prepared from whole 
blood collected with CPD as anticoagulant, whereas apheresis platelets were collected 
with ACD-A as anticoagulant. The apheresis procedure resulted in a platelet 
concentrate with high concentration, to which PAS-II was added, the proportion plasma 
to PAS being 40% to 60% (185). However, in vitro studies of these different platelet 
preparations, showed significantly lower values for adenine nucleotide levels, reduced 
consumption of glucose and production of lactate in apheresis PC using phosphate-free 
ACD as anticoagulant compared to BC-PC stored in phosphate-containing CPD. This 
indicates a difference attributable to the presence of phosphate. Platelet storage in  
PAS-II was compared with storage in a different PAS, designated PAS-III, which has a 
similar composition, except that phosphate is included as an additional component. 
 
In experiments 1 and 2, BC-PC in three platelet storage media were compared, i.e 
CPD-plasma, a medium consisting of 35% plasma and 65% PAS-II and a medium 
consisting of 35% CPD-plasma and 65% PAS-III. The consumption of glucose and 
production of lactate was significantly higher in PAS-III than PAS-II, although no 
significant differences in ATP and total adenine nucleotide content was noted. The 
levels of adenine nucleotides were similar in undiluted CPD-plasma. The significantly 
higher levels in plasma with regard to pH and bicarbonate as compared to PAS-II and 
PAS-II are probably related to plasma composition rather than metabolic differences. 
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Based on the metabolic parameters, the results suggest that PAS-II is comparable to 
PAS-III or undiluted CPD-plasma when BC-PC is stored in a suspension medium with 
35% CPD plasma inclusion. 
 
In experiment 3, BC-PC with only 20% plasma inclusion and two different PASs 
(PAS-II, PAS-III), with supplemented glucose, were compared. Pronounced differences 
in glucose consumption and lactate production, in combination with higher adenine 
nucleotide levels, were found with PAS-III. The levels of ATP on day 5 of storage was 
below 4.0 µmol/1011platelets observed with PAS-II, which is associated with loss of 
viability (74). Hence, these findings differed from what was observed with a higher 
proportion of CPD plasma included, and may be attributed to the presence of an 
alternate energy source in plasma, possibly free fatty acids. 
 
In experiment 4 apheresis PC in ACD-plasma and medium consisting of 35% ACD-
plasma and 65% PAS-II were compared. Significantly higher glucose consumption, 
lactate production and adenine nucleotide levels were found for undiluted ACD-plasma 
than with PAS-II. To investigate whether these differences were related to differences 
in phosphate concentration, storage of apheresis PC using either PAS-II or PAS-III was 
studied in experiment 5. The results were similar to those in experiment 3, i.e. 
significantly higher glucose consumption and lactate production in combination with 
higher adenine nucleotide levels were found with PAS-III. Thus, the difference 
between the effects of the PASs in experiment 5 could only be related to the 
concentration of phosphate. 
 
The conclusion based on the findings in these experiments is that the concentration of 
phosphate, like that of citrate or acetate, may have a significant influence on platelet 
metabolism when PASs are used. With respect to apheresis PCs using ACD as 
anticoagulant, our results suggests that the differences found is related to the 
concentration of phosphate. The presence of phosphate seems to be a critical factor to 
avoid low adenine nucleotide levels.  
The results for BC-PCs using CPD anticoagulant suggest that PAS-III which contains 
phosphate in addition to citrate and acetate, is preferable to PAS II when the plasma 
included in the suspension medium is less than 35% of the volume. 
 
4.4 PAPER IV 
Gamma irradiation: 
Paired studies of PCs from pooled buffy coats and from apheresis, stored in platelet 
additive solution/plasma, which were irradiated prestorage with cesium gamma 
irradiation equipment, showed similar in-vitro parameters compared to non-irradiated 
controls at all time-points during storage for 7 days. The in-vitro parameters were 
similar to those previously observed during storage of PCs prepared in the same way, 
and were all above the ranges associated with poor storage conditions (73). 
 
X-ray irradiation: 
For both groups of studied platelets, i. e. apheresis platelets, stored in platelet additive 
solution/plasma and in 100% plasma, and prestorage irradiated with X-ray equipment, 
the results are in the range previously reported for platelets prepared as in the present 
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study (186). None of the studied parameters proved any statistically significant 
difference between the groups at any time-point during storage for 7 days. 
 
The present study confirms the findings of previous published studies on the effects of 
gamma irradiation by radioactive sources. A wide variety of platelet preparations have 
been included such as platelets derived from whole blood and apheresis with different 
additive solutions/plasma combinations and for various length of 
storage(187),(146),(147),(148-152). Although some diverging results regarding studied 
parameters have been reported, the majority of previous studies have not shown any 
major deleterious effects. 
 
However, there are few studies on the effects of gamma irradiation by X-ray technique 
on blood components, and platelets in particular. The studies have focused mainly on 
red cells (188-190), and data indicate no significant difference between gamma 
irradiation and the X-ray technique on quality parameters. The present study includes 
X-ray irradiated platelets which have been stored for a prolonged period of time, which 
is an advantage from a logistic point of view.  
 
The present results indicate that prestorage irradiation of platelets, with either X-ray or 
cesium based techniques, causes minor changes compared with non-irradiated controls, 
of which none were statistically significant. The studied parameters after irradiation are 
within the normal range, and meet the quality requirements at all time points. 
 
Whether these similar in vitro results translate into a comparable clinical outcome may 
not be definitely answered. In a recent study (191) the corrected count increment (CCI) 
was analyzed after transfusion of fresh and stored buffy-coat derived gamma irradiated 
platelets in T-Sol to 60 allogeneic haematopoietic progenitor cell transplant recipients. 
Transfusion of fresh platelets resulted in a successful increment at both 1 and 24 hrs 
after transfusion. Transfusion of stored platelets resulted in a successful increment at  
1 h after transfusion, but a less successful increment was noted at 24 h.  
 
Taken together, this study concludes that pre-storage irradiation with both gamma and 
X-ray irradiation can be applied without compromising the in vitro quality of platelet 
preparations. Further in vivo studies are warranted however, to conclude to what extent 
these results corresponds with in vivo effects. 
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5 CONCLUDING REMARKS 
This thesis has focused on new techniques for preparation of blood components, with 
special emphasis on platelets. The studies all represent new options for blood 
component preparation, which has enhanced efficacy and safety. 
 
The major findings are 
Paper I- Whole blood filtration with a leukocyte reduction filter that saves platelets 
achieved effective leukocyte depletion meeting current standards and satisfactory 
recovery after filtration. The storage characteristics for RBCs and PCs were similar to 
those of standard preparations. The whole blood in-line filter saving platelets is a new 
option for whole blood processing, which may simplify leukocyte depletion and blood 
component preparation. 
 
Paper II- Automated preparation of PC from pooled buffy coats by the OrbiSac system 
with in-line leukocyte reduction filter is equivalent to the previous manual techniques 
regarding in vitro characteristics during storage for 7 days. The PCs are characterized 
by high recovery of platelets and sufficiently low leukocyte counts, and meet current 
quality criteria according to European standards.  
The selection of buffy coats and the uniform recovery resulted in reduced variation of 
platelet content.  
 
Paper III- The findings indicate that the concentration of phosphate, like that of citrate 
and acetate, has a significant influence on platelet metabolism when PASs are used, and 
is a critical factor to avoid low adenine nucleotide levels.  
The results for BC-PCs using CPD anticoagulant suggest that PAS-III which contains 
phosphate in addition to citrate and acetate, is preferable to PAS- II when the plasma 
included in the suspension medium is less than 35% of the volume. 
 
Paper IV- Prestorage irradiation of platelets, either with X-ray or cesium based 
techniques, causes minor changes compared with non-irradiated controls. The studied 
parameters after irradiation are within the range previously reported for platelets 
prepared with similar techniques, and meet the quality requirements at all time-points 
during storage up to seven days.  
 
To what extent these results corresponds with the in vivo effects is still not entirely 
clear, and further in vivo studies are warranted.  
 
As a final remark, the author wish to note, that during the time since the publication of 
these data further development has been done in the field, especially with regard to 
PASs and automation. 
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6 FUTURE PLANS 
6.1 PATIENT STUDY  
A platelet transfusion study has been started, with the aim to compare the clinical 
effects of platelets from pooled buffy coats stored in a new type of additive solution, 
PASIIIM, to those stored in the additive solution that has been used previously, PAS- 
II. The primary hypothesis being an increased platelet count increment after transfusion 
of platelets stored in PAS-IIIM compared to PASII due to decreased activation in vitro. 
PAS-IIIM has been used at our clinic since 2010, and is currently used in other 
European countries, and data from transfusion studies are warranted. 
Patients treated with allogeneic hematopoietic stem cell transplantation with 
myeloablative therapy are included. Children (<50 kg), known alloimmunization to 
platelet antigens (HLA, HPA) will not be included. 
The patients will receive either PAS-II the first time after the transplantation, and then 
PASIIIM, or reverse. Each patient is transfused at two occasions within the study. 
Samples will be taken before and after (1 and 24 hours) the transfusion of platelets to 
analyze platelet count increment and corrected count increments. The intervals between 
the transfusions will be recorded, in order to evaluate if this is increased after 
transfusion with the new PAS. 
In addition, clot formation analysis of whole blood, by thrombocytelastography 
(ROTEM) will be performed before and (1 hour) after transfusion.  
 
6.2 PNEUMATIC TUBE TRANSPORT 
Pneumatic tube systems (PTS) reduce the workload and turnaround time of 
laboratories. Blood components, including platelets, should be of the highest quality 
possible, but so far, there is few data (192) regarding the effects on platelets  by 
transport via a dedicated PTS, or if platelets age and number of runs has an effect. The 
aim of this study is to evaluate the in vitro effects of PTS transport on the quality of 
fresh, stored and returned platelets prepared from pooled buffy coats stored in 
approximately 70% PAS (PAS-IIIM). 
 
6.3 WASHING OF PLATELETS 
For patients with previous anaphylactic transfusion reactions, washing of platelet 
concentrates, either manually or with cell processors is performed to remove the 
suspension medium. This process has been evaluated by several authors, including 
platelet in-vitro parameters after washing with various solutions (193),(193, 194). 
A Japanese centre has recently evaluated washing of PLTs with Haemonetics ACP 215, 
a device used at our clinic for washing of erythrocytes. To use this equipment for 
washing of platelets as well is a new option, with the advantage of washing in a closed 
system, which may allow storage of washed PCs for more than a few hours after 
washing. 
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7 SVENSK SAMMANFATTNING  
Blodtransfusion har under den senare hälften av 1900-talet kommit att få en allt större 
betydelse inom sjukvården. Laboratoriespecialiteten Transfusionsmedicin spänner 
numer över ett stort kunskapsområde, vari bl.a. ingår att välja ut lämpliga blodgivare 
och tappningsteknik, uppdelning av blodet i beståndsdelar (komponenter) och förvaring 
av dessa. Från en blodgivning kan blodet delas upp i röda blodkroppar, plasma och 
lättcellskoncentrat, där majoriteten av trombocyterna finns. Fyra till sex 
lättcellskoncentrat poolas för att framställa ett trombocytkoncentrat (transfusionsdos) 
till en vuxen patient. Trombocytkoncentrat kan också framställas med aferesteknik, 
genom att blodet från en givare centrifugeras kontinuerligt i en särskild utrustning, 
varvid trombocyterna avskiljs och samlas upp, och resten av blodet ges åter till givaren. 
 
Sedan 1970-talet är uppdelning av helblod i komponenter den gängse rutinen, dels 
p.g.a. att det möjliggör att patienterna kan transfunderas med de celler som behövs, och 
dels p.g.a. att förvaring av de olika cellerna kan optimeras. Utveckling av 
centrifugeringsteknik och plastmaterial har varit av stor betydelse för att uppfylla krav 
på sterilitet, renhet och kvalitet hos de framställda komponenterna. De 
framställningsmetoder som används ska vara skonsamma, för att varken skada cellerna 
eller ha negativ inverkan på deras funktion. 
 
Studier av de olika blodcellernas ämnesomsättning har lett fram till kunskaper om 
bättre förvaringsbetingelser, vilket inkluderat användande av tillsatslösningar för röda 
blodkroppar och trombocyter. Andra aspekter av blodkomponentframställning som 
utvecklats under de senaste årtiondena är metoder att reducera antalet vita blodkroppar i 
blodkomponenter och metoder att standardisera cellinnehållet i koncentrat av 
trombocyter.  
 
Det finns många fördelar med att filtrera blodkomponenter för att avlägsna vita 
blodkroppar, t.ex. minskad risk för transfusionsreaktioner med feber, utveckling av 
antikroppar mot vita blodkroppar och överföring av vissa virus (t.ex. cytomegalovirus, 
CMV). I många länder har man infört filtrering av alla blodkomponenter, och i Sverige 
filtreras numer en majoritet av alla blodkomponenter. 
 
För patienter med nedsatt immunförsvar, t ex. efter transplantation med blodstamceller, 
eller för tidigt födda barn under nyföddhetsperioden, finns det dessutom behov av att 
bestråla blodkomponenter innan transfusion, för att förhindra att medföljande vita 
blodkroppar leder till en immunologisk reaktion (s. k. graft versus host disease; 
transplantat mot värd-sjukdom) som ofta har dödlig utgång. Bestrålningsutrustning med 
cesium som radioaktiv källa har oftast använts, men under senare år har även 
röntgenutrustning avpassad för bestrålning av blodkomponenter blivit tillgängliga. 
 
Undersökningarna i denna avhandling tar upp nya sätt att framställa blodkomponenter, 
med särskilt fokus på trombocyter: 
1) Studie av helblodsfilter som avlägsnar vita blodkroppar men släpper igenom 
trombocyter, visar att tillräckligt låga nivåer av kvarvarande vita blodkroppar, och hög 
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andel av erytrocyter och trombocyter finns kvar efter filtrering, och har god kvalitet 
som bibehålls under förvaring. 
2) Studie av automatiserad framställning av filtrerade trombocyter med OrbiSac, visar 
att metoden framställer trombocytkoncentrat med innehåll av trombocyter och 
kvarvarande vita blodkroppar som uppfyller gällande kvalitetskrav och bibehåller god 
kvalitet under förvaring. Genom att den automatiserade metoden ger reproducerbara 
utbyten av celler och genom att välja ut vilka lättcellskoncentrat som ska ingå i 
trombocytkoncentratet, kan man minska variationen i trombocytantal mellan de olika 
trombocytkoncentraten. 
3) Undersökning av effekter av fosfat i tillsatslösningar för trombocyter, har visat att 
fosfat är en nödvändig ingrediens i tillsatslöningar, för att bibehålla nivåer av 
adeninnukleotider som behövs för cellernas viabilitet. 
4) Undersökning av effekt av gamma- och röntgenbestrålning på trombocyter har inte 
kunnat påvisa någon negativ effekt på trombocyter under förvaring upp till 7 dagar. 
 
Det bör dock noteras att dessa laboratorieundersökningar (in vitro) bör kompletteras 
med undersökningar av blodkomponenternas effekt vid transfusion till patienter (in 
vivo). 
 
Sammantaget ger dessa nya tekniker och tillsatslösningar möjlighet att öka 
effektiviteten och säkerheten vid framställning av blodkomponenter. Vidare utveckling 
har också ägt rum inom området, framför allt vad gäller tillsatslösningar och nya 
utrustningar för automatiserad framställning av blodkomponenter. 
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